USP Will Develop Guidelines for Medicare Drug Benefit

OCTOBER 01, 2004

Acting on a request from the Department of Health and Human Services, the United States Pharmacopeia (USP) has entered into an agreement with the Centers for Medicare and Medicaid Services (CMS) to create "Model Guidelines" for the new Medicare drug benefit program. These guidelines are being developed in response to the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003.

In addition to developing Model Guidelines, the USP's tasks will include conducting public outreach for feedback regarding the guidelines, providing a comprehensive listing of all drugs in each category, and providing a proposed plan for revision of the guidelines as needed.

Pharmacy benefit managers may use the classes and categories developed by the USP and prescription drug plan sponsors as a foundation for designing their formularies under the Medicare drug law. CMS will use the guidelines to help assess plans submitted by insurers. The Model Guidelines, and the assignment of drugs to any class or category, are made only for the purpose of plan design evaluation under Part D of MMA and will not affect any other activity or activities related to the legislation.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.